Discontinuation of ocrelizumab
| Patients who discontinued, n (%) | 43 (12.1) |
| Median time in months to discontinuation (IQR) | 10.8 (6.1–18.9) |
| Median age of those discontinued (IQR) | 57.8 (45.8–63.7) |
| Reasons for discontinuation*, n (%) | |
| Pregnancy | 2 (4.7) |
| Cost/insurance issues | 2 (4.7) |
| Side effects | 24 (55.8) |
| Safety concerns/issues | 13 (30.2) |
| Relapse | 6 (14.0) |
| Clinical progression | 9 (20.9) |
| Death | 4 (9.3) |
| Among those who discontinued due to side effects†, n (%) | N=24 |
| Recurrent infections | 9 (39.1) |
| Fatigue/malaise | 13 (56.5) |
| Weakness | 3 (13.0) |
| Anxiety/depression | 3 (13.0) |
| Headache | 2 (8.7) |
| Sore throat | 2 (8.7) |
| Respiratory issues | 3 (13.0) |
| Cancer | 2 (8.7) |
| Hair loss | 1 (4.3) |
*Except for death, some patients had more than one reason given for discontinuation.
†Some patients discontinued due to more than one side effect.